Category Archives: Global News Feed

CALGARY, Alberta, Oct. 28, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in two upcoming virtual conferences in November 2020.

Read more from the original source:
XORTX Participation in Virtual Conferences

– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years –

Follow this link:
Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020

Newly created position to focus on driving growth within the Veterans Administration, Department of Defense and other government channels Newly created position to focus on driving growth within the Veterans Administration, Department of Defense and other government channels

The rest is here:
electroCore, Inc. Appoints Business Development Leader and US Navy Veteran Sylvester Steele as VP and General Manager of Government Channels Business...

Neumentum to receive $3MM upfront payment and is eligible to receive total development, regulatory and sales-based milestones of up to an additional $50MM plus royalties Neumentum to receive $3MM upfront payment and is eligible to receive total development, regulatory and sales-based milestones of up to an additional $50MM plus royalties

Continue reading here:
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China

Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF

Continue reading here:
Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

Read the original here:
Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung...